TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model

BACKGROUND: Osteosarcoma (OS) is the most common primary malignant bone tumour. Unfortunately, no new treatments are approved and over the last 30 years the survival rate remains only 30% at 5 years for poor responders justifying an urgent need of new therapies. The Mutt homolog 1 (MTH1) enzyme prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Moukengue, Brice, Brown, Hannah K, Charrier, Céline, Battaglia, Séverine, Baud'huin, Marc, Quillard, Thibaut, Pham, Therese M, Pateras, Ioannis S, Gorgoulis, Vassilis G, Helleday, Thomas, Heymann, Dominique, Berglund, Ulrika Warpman, Ory, Benjamin, Lamoureux, Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063190/
https://www.ncbi.nlm.nih.gov/pubmed/32151797
http://dx.doi.org/10.1016/j.ebiom.2020.102704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063190/
https://www.ncbi.nlm.nih.gov/pubmed/32151797
http://dx.doi.org/10.1016/j.ebiom.2020.102704

Ejemplares similares